1) Canadian Biotech Issuers Prepare for Clinical and Regulatory Milestones Several Canadian small‑ and mid‑cap biotech companies are approaching material disclosure windows tied to Phase 1/2 readouts, Health Canada submissions, …
DAYFILE:
